160,631 Shares in Elanco Animal Health Incorporated $ELAN Purchased by First National Bank of Omaha

First National Bank of Omaha acquired a new position in shares of Elanco Animal Health Incorporated (NYSE:ELAN) during the 2nd quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The fund acquired 160,631 shares of the company’s stock, valued at approximately $3,974,000.

Other hedge funds and other institutional investors have also added to or reduced their stakes in the company. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. bought a new position in shares of Elanco Animal Health during the 1st quarter valued at approximately $2,065,000. Goldman Sachs Group Inc. lifted its position in Elanco Animal Health by 104.5% in the first quarter. Goldman Sachs Group Inc. now owns 4,787,394 shares of the company’s stock worth $50,268,000 after buying an additional 2,445,872 shares during the last quarter. Empowered Funds LLC lifted its position in Elanco Animal Health by 35.2% in the first quarter. Empowered Funds LLC now owns 15,835 shares of the company’s stock worth $166,000 after buying an additional 4,121 shares during the last quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC boosted its stake in Elanco Animal Health by 4.5% during the first quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 1,793,337 shares of the company’s stock worth $18,830,000 after buying an additional 76,408 shares during the period. Finally, Arrowstreet Capital Limited Partnership boosted its stake in Elanco Animal Health by 2,006.9% during the second quarter. Arrowstreet Capital Limited Partnership now owns 310,383 shares of the company’s stock worth $4,432,000 after buying an additional 295,651 shares during the period. 97.48% of the stock is currently owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

Several brokerages have recently weighed in on ELAN. Morgan Stanley increased their target price on shares of Elanco Animal Health from $23.00 to $26.00 and gave the company an “equal weight” rating in a research note on Wednesday, July 22nd. Weiss Ratings raised shares of Elanco Animal Health from a “sell (d)” rating to a “sell (d+)” rating in a research note on Friday, July 31st. UBS Group boosted their target price on Elanco Animal Health from $31.00 to $33.00 and gave the company a “buy” rating in a research report on Thursday, August 6th. Wall Street Zen downgraded Elanco Animal Health from a “strong-buy” rating to a “buy” rating in a report on Sunday, May 24th. Finally, Citigroup raised their price target on Elanco Animal Health from $30.00 to $31.00 and gave the stock a “buy” rating in a research note on Thursday, May 7th. One investment analyst has rated the stock with a Strong Buy rating, nine have assigned a Buy rating, two have assigned a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and a consensus target price of $29.09.

Elanco Animal Health Price Performance

Elanco Animal Health stock opened at $23.63 on Wednesday. The company has a debt-to-equity ratio of 0.58, a current ratio of 2.05 and a quick ratio of 1.10. The stock has a market cap of $11.80 billion, a price-to-earnings ratio of -57.63, a price-to-earnings-growth ratio of 1.42 and a beta of 1.67. The firm has a 50-day moving average of $24.54 and a two-hundred day moving average of $24.01. Elanco Animal Health Incorporated has a 1 year low of $17.11 and a 1 year high of $27.98.

Elanco Animal Health (NYSE:ELAN) last posted its quarterly earnings results on Wednesday, August 5th. The company reported $0.34 earnings per share for the quarter, beating the consensus estimate of $0.27 by $0.07. Elanco Animal Health had a negative net margin of 3.96% and a positive return on equity of 8.13%. The firm had revenue of $1.37 billion during the quarter, compared to the consensus estimate of $1.31 billion. During the same quarter in the previous year, the firm posted $0.26 earnings per share. The company’s revenue was up 10.2% on a year-over-year basis. Elanco Animal Health has set its Q3 2026 guidance at 0.190-0.220 EPS and its FY 2026 guidance at 1.100-1.160 EPS. On average, research analysts forecast that Elanco Animal Health Incorporated will post 1.12 earnings per share for the current year.

Insider Transactions at Elanco Animal Health

In other news, Director Paul Herendeen purchased 10,000 shares of the company’s stock in a transaction dated Friday, August 7th. The shares were acquired at an average price of $23.68 per share, with a total value of $236,800.00. Following the transaction, the director owned 111,687 shares of the company’s stock, valued at $2,644,748.16. This represents a 9.83% increase in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, insider Shiv O’neill purchased 3,998 shares of the business’s stock in a transaction dated Tuesday, August 18th. The shares were purchased at an average price of $23.58 per share, for a total transaction of $94,272.84. Following the purchase, the insider owned 87,832 shares of the company’s stock, valued at approximately $2,071,078.56. This trade represents a 4.77% increase in their position. Additional details regarding this purchase are available in the official SEC disclosure. Insiders acquired a total of 23,198 shares of company stock worth $537,109 over the last quarter. 1.14% of the stock is owned by corporate insiders.

Elanco Animal Health Company Profile

Elanco Animal Health Inc is a global leader in animal health dedicated to improving food and companion animal well-being. The company develops, manufactures and markets a range of products, including parasiticides, vaccines, antibiotics and feed additives designed to prevent and treat disease in livestock and pets. Elanco’s portfolio spans both food-producing animals—such as cattle, swine, poultry and aquaculture—and companion animals, with offerings that support parasite control, pain management and infectious disease prevention.

Originally founded as the animal health division of Eli Lilly and Company in the mid-20th century, Elanco was spun off into an independent publicly traded company in 2018.